Clinical Trials Logo

Clear Cell Renal Cell Carcinoma clinical trials

View clinical trials related to Clear Cell Renal Cell Carcinoma.

Filter by:

NCT ID: NCT05879497 Recruiting - Clinical trials for Clear Cell Renal Cell Carcinoma

68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single-center, single-arm phase 2 study in patients with clear cell renal cell carcinoma and metastasis or recurrence suspicion. The goal is to determine the sensitivity and specificity of 68Ga-NY104 PET/CT in patients with clear cell renal cell carcinoma and metastasis or recurrence suspicion

NCT ID: NCT05861778 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

ZIRDOSE-CP
Start date: June 26, 2023
Phase: Phase 1
Study type: Interventional

The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese patients with indeterminate renal masses or Suspected Recurrent Renal Clear Cell Carcinoma

NCT ID: NCT05795595 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Start date: March 13, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.

NCT ID: NCT05728515 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma

Start date: December 25, 2021
Phase: Early Phase 1
Study type: Interventional

The goal of this pilot clinical trial is to see the potential application of a CAIX targeted PET. tracer in patients with clear cell renal cell carcinoma. The main question[s] it aims to answer are: - The biodistribution of the PET tracer - Whether RCC lesions can be identified by the PET tracer Participants will undergo 68Ga-NY104 PET/CT scan and images will be reviewed by nuclear medicine specialists.

NCT ID: NCT05663710 Active, not recruiting - Advanced Cancer Clinical Trials

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Start date: June 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).

NCT ID: NCT05620134 Recruiting - Cancer Clinical Trials

Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Start date: October 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer.

NCT ID: NCT05536141 Recruiting - Solid Tumors Clinical Trials

A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors

ARC-20
Start date: October 26, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of AB521 when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC).

NCT ID: NCT05520099 Recruiting - Colorectal Cancer Clinical Trials

Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

CYBRID-02
Start date: June 26, 2023
Phase:
Study type: Observational

The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.

NCT ID: NCT05433142 Recruiting - Clinical trials for Clear Cell Renal Cell Carcinoma

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Start date: June 13, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

NCT ID: NCT05432947 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients

Start date: April 14, 2022
Phase: N/A
Study type: Interventional

PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors, including clear cell renal cell carcinoma (ccRCC). This makes it a potentially imaging target for the detection of ccRCC. This pilot study was designed to evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 18F-FDG PET/CT in the same group of ccRCC patients.